University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 2N-13-6


A Randomized Phase II Study of Epigenetic Priming with Azacitidine and Entinostat Prior to Nivolumab versus Nivolumab Alone in Subjects with Recurrent Metastatic Non-Small Cell Lung Cancer

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jorge Nieva, M.D.
Other Trial Staff:  Deborah Fridman, Coordinator, Victoria Amran, D.M., Lagrimas Ilagan, D.M., Gina Tse, R.N., Kristy Sartor Massopust, Coordinator, Shamim Jhimlee, Coordinator, Eduardo Mejia, D.M., Laurie De Oliveira, Coordinator, Atessa Kiani, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.